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Objectives: To assess the potential benefits of the hemodynamic superiority of
stentless valves, we conducted a case-match study among patients who
underwent aortic valve replacement with two types of porcine bioprostheses:
the Toronto SPV and the stented Hancock II bioprosthesis. Methods: Preop-
erative clinical variables predictive of death after aortic valve replacement were
determined by a stepwise logistic regression analysis in a series of 908
consecutive patients who received porcine aortic bioprostheses during a
14-year interval. Advanced age, New York Heart Association functional class
IV, left ventricular ejection fraction of less than 30%, and coronary artery
disease were independent predictors of death. On the basis of these four
variables, 198 pairs of patients who survived aortic valve replacement with
stentless and stented porcine valves were matched. The follow-up, truncated to
the shortest interval for each matched pair, was 43 6 24 months for both
groups. Results: At 8 years the actuarial survival was 91% 6 4% for the Toronto
SPV group and 69% 6 8% for the Hancock II group (p 5 0.006); the freedom
from cardiac-related death was 95% 6 4% for the Toronto SPV and 81% 6 8%
for the Hancock II (p 5 0.01); the freedom from any valve-related complication
was 81% 6 5% for the Toronto SPV and 50% 6 10% for the Hancock II (p 5
0.008). A Cox proportional hazard model demonstrated a significant reduction
in cardiac mortality rates and valve-related morbidity in patients who received
the Toronto SPV bioprosthesis. Conclusions: Although it is possible that
confounding factors may have played a role in the clinical outcomes of this
case-control study, the study suggests that aortic valve replacement with a stentless
porcine valve enhances survival. This is believed to be due to the hemodynamic
superiority of these valves. (J Thorac Cardiovasc Surg 1998;116:236-41)
The Toronto SPV bioprosthesis (St. Jude Medical,Inc., St. Paul, Minn.) was developed to improve the
hemodynamic performance of porcine aortic valves
and to enhance their durability.1, 2 The Toronto SPV
bioprosthesis is minimally obstructive to blood flow;
when implanted in patients with increased left ventric-
ular mass, it allows for complete remodeling of the left
ventricle within the first 3 years.3 Color Doppler
assessment of blood flow across the Toronto SPV
bioprosthesis indicates that it resembles that of a
normal aortic valve.4 The hemodynamic superiority of
this valve has been documented by several investiga-
tors.3-5 Although the issue of the durability of this
bioprosthesis remains unknown, our experience with
29 custom-made stentless porcine aortic valves sug-
gests that its durability may not be better than that of
stented bioprostheses.6 Thus the only obvious advan-
tage of a stentless porcine aortic valve is its hemody-
namic performance. This may be important for late
survival after aortic valve replacement because persis-
tent left ventricular hypertrophy is associated with an
increased risk of death.7, 8
This study was carried out to compare the late
outcomes of aortic valve replacement with stentless
and stented porcine aortic valves.
Patients and methods
From 1982 to 1996, 908 patients underwent isolated
aortic valve replacement (AVR) with two types of porcine
aortic valves at The Toronto Hospital. The Hancock II
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bioprosthesis (Medtronic, Minnesota, Minn.) was used in
666 patients, and the Toronto SPV bioprosthesis was used
in 242 patients. The Hancock II bioprosthesis was used
throughout the period of study whereas the Toronto SPV
bioprosthesis was used only since 1987. All patients were
followed up at annual intervals, and only eight patients
with the Hancock II and one patient with the Toronto
SPV bioprosthesis were lost to follow-up.
The Toronto SPV bioprosthesis was an investigational
device during this study, and it was implanted in patients
who fulfilled the following requirements: older than 34
years of age, no active aortic valve infection, no renal
failure requiring dialysis, and an expected life span of at
least 2 years. The Hancock II was implanted whenever
appropriate. Because of these differences in patient selec-
tion, a case-control study was developed on the basis of
preoperative variables predictive of death after AVR.
These variables were identified by a stepwise logistic
regression analysis for the entire patient population with
porcine bioprostheses. The following preoperative vari-
ables were independent predictors of death after AVR:
advanced age, New York Heart Association functional
class IV, left ventricular ejection fraction below 30%, and
coronary artery disease. With this information, a case-
match study was developed on the basis of the patients’
age (65 years), New York Heart Association functional
class (I, II, III together, or IV ), left ventricular ejection
fraction (higher or lower than 30%), and coronary artery
disease. Only survivors of the operation were entered into
the case-match study. One hundred ninety-eight pairs of
patients were matched. Table I shows the clinical profile
of the matched patients. Both groups had the same
incidence of associated diseases, such as peripheral vas-
cular disease, diabetes, hypertension, and chronic obstruc-
tive lung disease. There were no differences in the intra-
operative management of patients as far as conduction of
anesthesia, cardiopulmonary bypass, or myocardial pro-
tection.
The follow-up was complete in all patients. Because the
duration of the follow-up was different for the two groups
of patients, follow-up times were truncated to the shortest
interval for each matched pair of patients. For this reason,
the mean follow-up was 43 6 24 months (range 3 to 109
months) for both groups. Postoperative complications
were analyzed according to the “Guidelines for Reporting
Morbidity and Mortality after Cardiac Valvular Opera-
tions.”9 Events occurring after a truncated follow-up
interval were censored.
All statistical analyses were performed with the SAS
(SAS Institute, Inc., Cary, N.C.) and the BMDP/DYN
(BMDP Statistical Software, Berkeley, Calif.) programs.
The clinical profile of the two groups was compared by x2
analysis. Longitudinal data, such as actuarial survival and
freedom from morbid events, were estimated by the
product-limit or by the Kaplan-Meier method. Values
were expressed as means and the standard errors of the
means. The longitudinal comparisons of the two groups of
patients were evaluated by the Mantel-Cox statistic. The
risk-adjusted benefit of the Toronto SPV bioprosthesis
was evaluated multivariately in a Cox proportional hazard
model.
Results
Patient survival. There were 9 deaths in the
group who received the Toronto SPV bioprosthesis
and 25 deaths in the group who received the Han-
cock II (p 5 0.004). Fig. 1 shows the actuarial
survival for both groups. The survival was signifi-
cantly better in the Toronto SPV group (p 5 0.006).
There were 5 cardiac deaths in the Toronto SPV
group and 15 cardiac deaths in the Hancock II
group. Fig. 2 shows the freedom from cardiac death
in both groups of patients. The freedom from car-
diac death was significantly better in the Toronto
SPV group (p 5 0.01). There was only one valve-
related death in the Toronto SPV group and four
deaths in the Hancock II group. The freedom from
valve-related death at 8 years was 99% 6 1% for the
Table I. Clinical profile of matched patients
Toronto
SPV
Hancock
II
p
Value
No. of patients 198 198
Age (yr)* 62 6 11 62 6 11 0.66
Range 34-80 29-80
Sex
Male (%) 135 (68) 145 (73) 0.27
Female (%) 63 (32) 53 (27)
Atrial fibrillation/flutter (%) 12 (6) 12 (6) 1.00
New York Heart Association
Functional class I, II, III (%) 172 (87) 172 (87) 0.99
Functional class IV (%) 26 (13) 26 (13)
Left ventricular ejection
fraction
.30% (%) 164 (83) 164 (83) 0.99
#30% (%) 34 (17) 34 (17)
Coronary artery disease (%) 63 (32) 63 (32) 0.99
Single vessel 12 11
Double vessel 14 14
Triple vessel 37 38
Aortic valve lesion
Stenosis (%) 148 (74) 94 (47)
Insufficiency (%) 25 (13) 54 (27) 0.001
Mixed (%) 25 (13) 49 (13)
Bioprosthesis size (mm)
19 (%) 1 0 0.001
21 (%) 4 (2) 10 (5)
22 (%) 3 (2) 0
23 (%) 17 (9) 53 (27)
25 (%) 53 (27) 61 (31)
27 (%) 62 (31) 56 (28)
29 (%) 58 (29) 18 (9)
Patch enlargement of the aortic
annulus (%)
0 43 (22) 0.001
Body surface area (m2)* 1.84 6 0.21 1.85 6 0.22 0.49
Aortic crossclamp time (min)* 84 6 23 69 6 27 0.001
Cardiopulmonary bypass
time (min)*
105 6 30 94 6 35 0.002
*Expressed as mean 6 standard deviation.
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Toronto SPV and 97% 6 2% for the Hancock II
(p 5 not significant). Table II shows the causes of
late deaths.
Thromboembolism. There were 10 thromboem-
bolic events (two strokes and eight transient isch-
emic attacks) in the Toronto SPV group and 14 (six
strokes and eight transient ischemic attacks) in the
Hancock II group. The freedom from thromboem-
bolic complications at 8 years was 91% 6 4% for the
Toronto SPV and 86% 6 5% for the Hancock II
(p 5 0.07).
Infective endocarditis. Infective endocarditis de-
veloped in two patients with the Toronto SPV (one
early and one late), and in six patients with the
Hancock II (one early and five late). The freedom
from infective endocarditis at 8 years was 98% 6
2% for the Toronto SPV and 94% 6 2% for the
Hancock II (p 5 0.05).
Reoperation. Redo AVR was necessary in two
patients with the Toronto SPV bioprosthesis (both
for endocarditis) and in eight patients with the
Hancock II (six for endocarditis and two for primary
tissue failure). The freedom from redo AVR at 8
years was 98% 6 2% for the Toronto SPV biopros-
thesis and 83% 6 9% for the Hancock II (p 5 0.03).
Valve-related morbidity. Fig. 3 shows the free-
dom from any valve-related complication for both
groups of patients. The difference was statistically
significant in favor of the Toronto SPV bioprosthe-
sis (p 5 0.05).
Predictors of clinical outcomes by multivariate
analysis. The following variables were submitted
to a Cox proportional hazard model: age (,65
years and $65 years), left ventricular dysfunction
(ejection fraction, .30% and #30%), New York
Heart Association (classes I through III and class
IV), coronary artery disease, and valve type (To-
ronto SPV and Hancock II). Aortic stenosis was
also tested because there were more patients with
aortic stenoses in the Toronto SPV bioprosthesis
than in the Hancock II group (Table I) but it was
not a predictor of outcome. The results of this
analysis are shown in Table III. The overall
mortality rate, the cardiac mortality rate, and the
risk of valve-related morbidity rate after AVR
with the Toronto SPV bioprosthesis were lower
than with the Hancock II.
Discussion
This case-control study shows that the late clinical
outcomes after AVR with an SPV are significantly
better than those of a stented porcine valve. Al-
though it is possible that these differences may have
been due to bias in patients’ selection or other
confounding factors not detected in our cardiovas-
cular database, we believe that our findings are a
consequence of AVR with a bioprosthesis with
excellent hemodynamic features.
Assessing potential bias and confounding factors.
Patients were matched by an epidemiologist who
had no knowledge of the valves or of the clinical
outcomes. Careful review of each patient’s clinical
profile failed to indicate any bias as far as the
severity of the cardiac disease or of the associated
diseases such as diabetes, hypertension, peripheral
vascular disease, renal function impairment, or any
malignancy that may have affected the surgeon’s
choice of the valve in the matched patients. How-
ever, there was a higher number of noncardiac
deaths among patients with the Hancock II valve,
Fig. 1. Actuarial survival after AVR with Toronto SPV and Hancock II (HAII) bioprostheses.
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and this finding could not be explained by examining
the preoperative variables.
Table I shows a higher incidence of aortic stenosis
among patients who received the Toronto SPV
bioprosthesis when compared with patients who
received the Hancock II bioprosthesis. This is prob-
ably due to the fact that the Toronto SPV biopros-
thesis was not implanted in patients with a dilated
aortic root. Nevertheless, aortic stenosis was not a
predictor of clinical outcomes by univariate analysis
(x2 and Fisher’s exact test) or multivariate analysis
(Cox regression analysis) in the entire population or
in any of its subgroups (Hancock II sampled and not
sampled or Toronto SPV).
To evaluate the potential bias of the Hancock II
patients, the sampled group of (198 patients) was
compared with the not sampled (468 patients). The
actuarial survival at 8 years was 69% 6 5% for the
sampled group and 70% 6 3% for the not sampled
group of Hancock II patients (p 5 0.34). The
freedom from cardiac deaths and the freedom from
valve-related deaths were also similar for the sam-
pled and not sampled groups of Hancock II.
The clinical outcomes after AVR with the To-
ronto SPV bioprosthesis have been exceptionally
good, particularly when compared with other re-
ports on stented bioprostheses.6, 10-13 In our experi-
ence with 242 patients with a mean age of 62 years
and coronary artery disease in one third of those
patients, the actuarial survival including the opera-
tive mortality rate was 89% at 9 years.6 Similarly, in
the premarked clinical trial involving over 600 pa-
tients (mean age, 67 years; coronary artery disease,
40%) sponsored by the manufacturer of this valve to
obtain its Food and Drug Administration approval,
the actuarial survival at 6 years was approximately
90%.10 The rates of valve-related complications
have also been lower than those observed with other
stented bioprostheses.6, 10-13 In most reports on late
outcomes after AVR with stented biologic valves,
the actuarial survival at 5 years ranged around 70%
to 80% and at 10 years ranged around 50% to
60%.11-13
Hemodynamic performance of the Toronto SPV
bioprosthesis. Numerous studies have shown that
the Toronto SPV bioprosthesis has excellent hemo-
dynamic features that are comparable with those of
the aortic valve homograft.3-5, 14 Serial echocardio-
graphic studies in large numbers of patients who
underwent an AVR with the Toronto SPV biopros-
thesis demonstrated a progressive reduction in the
mean transvalvular gradients and an increase in the
effective valve orifices during the first year after
implantation.3-4, 6 At the end of postoperative year
1, the mean transvalvular gradients have been con-
sistently below 5 mm Hg in all patients, regardless of
the size of valve implanted.3-6 This favorable hemo-
dynamic feature probably inhibits the stimulus re-
Fig. 2. Freedom from cardiac death after AVR with Toronto SPV and Hancock II bioprostheses.
Table II. Causes of late deaths
Toronto SPV Hancock II
Cardiac and valve-related deaths
Myocardial infarction/sudden 3 5
Congestive heart failure 1 6
Prosthetic valve endocarditis 1 2
Stroke 0 2
Noncardiac deaths
Cancer 2 5
Renal failure 0 2
Abdominal aortic aneurysm 0 2
Pneumonia 0 1
Cerebral aneurysm 1 0
Suicide 1 0
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sponsible for left ventricular hypertrophy, and remod-
eling of the ventricle begins soon after operation.3, 5
Although regression of left ventricular hypertrophy
also occurs after AVR with stented valves,15-17 most
patients still have residual hypertrophy after 2 to 3
years.16 Residual hypertrophy is rare after AVR with
the Toronto SPV bioprosthesis after postoperative
year 2.3 In addition, it has been shown that early
postoperative left ventricular function after AVR is
better with the Toronto SPV bioprosthesis than with
stented porcine and mechanical valves.5, 15 This obser-
vation may explain the relatively low operative mortal-
ity rate for AVR with the Toronto SPV bioprosthesis
in spite of longer aortic crossclamp times than with
stented valves.4-6 In our experience with porcine
valves, the operative mortality rate for AVR with the
Toronto SPV bioprosthesis was 0.8%, whereas for the
Hancock II it was 4%.4, 11
The long-term effects of residual left ventricular
hypertrophy after AVR are unknown, but the clin-
ical experience with systemic hypertension indicates
that left ventricular hypertrophy adversely affects
long-term survival.7, 8 Thus it is conceivable that
AVR with the Toronto SPV bioprosthesis enhances
survival because of its hemodynamic features. This
may well explain the differences in cardiac and
valve-related deaths in our case-control study. In-
deed, the major difference in clinical outcomes
between our two groups of patients was in the
number of late cardiac deaths. During a mean
follow-up of 43 months, one third as many late
deaths occurred in patients with the Toronto SPV
valve as in patients with the Hancock II bioprosthe-
sis. The frequency of valve-related complications
were also significantly lower in patients who re-
ceived stentless valves. This reduction in complica-
tions may also have indirectly affected survival.
Aortic valve homografts have excellent hemo-
dynamic features and, when implanted in the
subcoronary position, provide similar flows to the
normal aortic valve.14 Thus one would expect that
AVR with an aortic valve homograft would en-
hance late survival, which is what we found with
the SPV bioprosthesis. Although this may not
have been observed in the past, recently published
results on AVR with homograft indicate a survival
of 85% to 95% at 8 to 10 years, including opera-
tive mortality rates.18-20 Although the patient
population in those series were different from
ours, the results suggest that aortic valve ho-
Fig. 3. Freedom from any valve-related complication after AVR with Toronto SPV and Hancock II
bioprostheses.
Table III. Predictors of outcome by Cox
proportional hazard model
Outcome
Regression
coefficient
Hazard
ratio p Value
Overall deaths
Toronto SPV 20.92 6 0.40 0.40 0.0001
LV dysfunction 0.99 6 0.38 2.20
CAD 0.79 6 0.38 2.20
Age .65 years 0.78 6 0.40 2.18
Male gender 0.88 6 0.56 2.41
Cardiac-related deaths
Toronto SPV 21.49 6 0.65 0.37 0.004
LV dysfunction 1.09 6 0.53 2.98
Valve-related deaths None None NS
Valve-related morbidity:
Toronto SPV 20.66 6 0.35 0.52 0.054
LV, Left ventricle; CAD, coronary artery disease.
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mografts provide better clinical outcomes than
those obtained with stented biologic valves. Prob-
ably the same could be said about AVR with
pulmonary autograft because it is also a stentless
biologic valve with superlative hemodynamic qual-
ities. Finally, we have treated numerous patients
with patient-prosthesis mismatch after AVR when
mechanical and stented bioprostheses were im-
planted, but we have never documented a case of
patient-prosthesis mismatch in more than 500
AVRs with stentless biologic valves of all types.
Durability of the Toronto SPV bioprosthesis.
The Toronto SPV bioprosthesis has been used only
since July 1991. There has been no documented case
of primary tissue degeneration, but it has been used
almost exclusively in older patients.6, 10 However, we
implanted 29 custom-made stentless porcine aortic
valves similar to the Toronto SPV bioprosthesis just
over one decade ago,1 and the experience with those
valves suggests that their durability is no different from
that of stented porcine valves.6 If this is the case with
the Toronto SPV bioprosthesis, and if this valve in-
deed enhances the life span after AVR, the probability
of reoperation for valve failure will be greater with this
valve than with stented ones because more patients
will be at risk of outliving their bioprosthesis.
Limitations of the study. This was a retrospective
study, and the two groups of patients may have been
quite different in spite of our efforts to eliminate any
potential bias and to exclude any confounding factor
that may have influenced the clinical outcome. Other
limitations are the relatively small number of patients
in each group and the duration of follow-up.
Conclusions
This case-match study indicates that AVR with a
stentless porcine aortic valve provides better clinical
outcomes than with a stented porcine valve. The
patients’ survival, the freedom from cardiac deaths,
and the freedom from valve-related complications
were significantly better in patients with the stentless
valve. Unfortunately all observations made were
based on retrospective data with all their limitations
and potential bias. However, this information is a
compelling reason to believe that valves with supe-
rior hemodynamic performance have a beneficial
effect in the late results of AVR.
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